Comment from Aptalis Pharma US, Inc on Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Request for Nominations

Comment from Aptalis Pharma US, Inc.

• See Attached

• Public Submission
• Posted:
  03/10/2014
• ID:
  FDA-2013-N-1523-0009

• Agency:
  FDA
• RIN:
  Not Assigned
• Docket ID:
  FDA-2013-N-1523

• Organization:
• Submitter Name: